Perspective Therapeutics (CATX) Q1 2024 Earnings
CATX·Reported May 15, 2024·Before market open
Perspective Therapeutics reported Q1 2024 revenue of $325.0K, missed analyst consensus of $368.8K by $43.8K. Diluted EPS came in at $-0.20, beat the $-0.30 consensus by $0.10.
Revenue
$325.0Kmissed by $43.8K
Consensus: $368.8KDiluted EPS
$-0.20beat by $0.10
Consensus: $-0.30
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Perspective Therapeutics's Q1 2024 earnings report.
Perspective Therapeutics (CATX) reported Q1 2024 earnings on May 15, 2024 before market open.
Perspective Therapeutics reported revenue of $325.0K and diluted EPS of $-0.20 for Q1 2024.
Revenue missed the consensus estimate of $368.8K by $43.8K. EPS beat the consensus estimate of $-0.30 by $0.10.
You can read the 10-Q periodic report (0000950170-24-060427) directly on SEC EDGAR. The filing index links above go to sec.gov.